Navigation Links
Simcere Pharmaceutical Group to Announce Third Quarter 2011 Financial Results on Monday, November 14, 2011
Date:10/31/2011

NANJING, China, Oct. 31, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2011 on Monday, November 14, 2011, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Monday, November 14 at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:United States toll-free:+1.866.519.4004United States toll:

+1.718.354.1231China Domestic:

800.819.0121 China Domestic mobile:

400.620.8038 Hong Kong:

+852.2475.0994Please ask to be connected to Q3 2011 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 21357022.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:
:

+1.866.214.5335United States toll:

+1.718.354.1232The passcode for replay participants is 21357022. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:In the United States:Yehong Zhang

Cindy ZhengPresident

Brunswick GroupSimcere Pharmaceutical GroupTel: +1-212-333-3810Tel: +86-25-8556-6666 ext. 88In Beijing:In Hong Kong:Yue Yu

Joseph Lo Chi-LunBrunswick Group

Brunswick GroupTel: +86-10-5960-8600

Tel: +852-3512-5000  
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simceres Iremod Receives SFDA New Drug Approval
2. Simceres Branded Generic Formulation Biqi Passes EU-GMP Inspection
3. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
4. Simcere Pharmaceutical Group to Announce Second Quarter 2011 Financial Results on Tuesday, August 9, 2011
5. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
6. Simcere Pharmaceutical Group Filed 2010 Annual Report on Form 20-F
7. Simcere Announces Recent Progress of Qiangkes Registration
8. Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
10. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2010 Unaudited Financial Results on Tuesday, March 8, 2011
11. Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016   Click here ... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... a definitive agreement to acquire Valley Campus Pharmacy, ... ("TNH"), a leading specialty pharmacy that provides individualized ... California . In 2015, TNH generated approximately ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
(Date:4/28/2016)... 28, 2016   Acsis , a leading provider ... IT market research and advisory firm IDC has named ... MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 Vendor ... an assessment of the capabilities and business strategies of ... market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program ... to announce the launch of the GFCP Scoop in response to ... purpose of the GFCP Scoop site is to keep the gluten-free ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... Cosmetic dentistry is a fast-growing field as more patients are discovering the many different ... more about the options currently available to them and which ones might work for ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Reltok Nasal Products ... products for the head and neck/ear, nose and throat specialty, has added the KOTLER ... The KOTLER NASAL AIRWAY™ is a newly patented safety device secured by nasal ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, ... round of funding led by Eastside Partners, with participation from existing investor Martin ... customer base and accelerate its technology and product roadmap. , “Jvion ...
(Date:4/29/2016)... ... 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of ... them second place for Tampa’s Best Places to Work. They were ranked in the ... great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We work ...
Breaking Medicine News(10 mins):